The cell therapy industry is enjoying a period of unprecedented growth. The number of cell-based treatments transitioning from development to commercial manufacturing is forecast to continue growing dramatically over the next decade. This predicted growth rate can only be maintained by a parallel increase in the availability of therapeutic starting materials.
HemaCare scientists have just published a white paper on a new raw material sourcing paradigm that they hope will transform the industry.
The publication centers on dedicated donors; recallable donors who are reserved to specific research programs. The basic premise is that clients will be able to reserve self-identified recallable donors who possess physiological or demographic traits deemed beneficial to a particular research program.
Isolated immune cell populations support a wide variety of research and cell therapy applications. Because purification and preliminary characterization of immune cell subsets can be time-consuming and costly, many researchers prefer to purchase isolated immune cells rather than raw materials.
HemaCare and Cellero are ringing in the New Year with the aspiration to be bigger and better!
Both cell supply companies are joining forces under the umbrella of Massachusetts-based Charles River Laboratories. The new coalition is a major part of Charles River’s strategy to expand its research and development capacity, by acquiring the expertise needed to bring cellular therapies all the way from sourcing starting materials through to commercialization.
Recent studies suggest that mesenchymal stem cells (MSC) of the maternal decidua may prove to be an effective treatment for patients suffering from preeclampsia.
Preeclampsia is one of the most common causes of maternal and perinatal morbidity and mortality, affecting as high as 8% of pregnant women worldwide. It is a severe cardiovascular disorder that develops after 20 weeks of pregnancy and is characterized by a sudden onset of hypertension, swelling of the limbs and face, proteinuria, and adverse effects on various organs, including the kidneys and liver. If left untreated, maternal organ damage can occur, and the fetus can be deprived of sufficient blood flow and oxygen. Eclampsia (seizures) and HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count) may also ensue.